Sutro Biopharma is developing next generation antibody-drug conjugates, including dual payload ADCs. CEO Jane Chung walks us through their programs
- 1 hour ago
- 1 min read
She describes a dual payload ADC targeting TROP2 that is partnered with Astellas, as well as internal programs targeting tissue factor (currently in the clinic), integrin β6, and a dual payload ADC targeting PTK7.









.png)
